Ken Griffin Fusion Pharmaceuticals Inc. Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.9 - $21.32 $3.31 Million - $8.94 Million	419,253 Added 774.63%	473,376 $10.1 Million
Q4 2023 Feb 14, 2024	BUY	$2.48 - $9.65 $134,225 - $522,286	54,123 New	54,123 $520,000
Q4 2022 Feb 14, 2023	SELL	$2.1 - $3.34 $33,566 - $53,386	-15,984 Reduced 56.1%	12,510 $39,000
Q3 2022 Nov 14, 2022	BUY	$2.0 - $3.56 $56,988 - $101,438	28,494 New	28,494 $86,000
Q3 2020 Nov 16, 2020	SELL	$11.8 - $17.1 $3.84 Million - $5.56 Million	-325,001 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$17.0 - $17.78 $5.53 Million - $5.78 Million	325,001 New	325,001 $5.68 Million

93K

1.4K

Ticker FUSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,390,500
Description
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.